Ability Pharmaceuticals SL:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Ability Pharmaceuticals SL - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11206
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スペイン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ability Pharmaceuticals SL (Ability Pharma), formerly AB Therapeutics SL is a biopharmaceutical company that discovers and develops human therapeutics for the treatment of cancer and other indications. The company’s lead pipeline drug candidate includes ABTL0812, a new drug class of small molecules, developed for the treatment of lung and endometrial cancer. Ability Pharma’s pipeline also includes programs for other indications such as hematological cancers. The company offers treatment for lung, pancreatic and gynecological cancers. The company works in partnership with academic institutions to develop new drug candidates up to clinical proof of concept and later out-license them to pharmaceutical companies for development and marketing. Ability Pharma is headquartered in Barcelona, Spain.

Ability Pharmaceuticals SL – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Ability Pharma to Raise USD10.98 Million in Series A Financing 10
Ability Pharma Raises US$1.3 Million In Second Round Of Financing 11
Licensing Agreements 12
SciClone Pharma Enters into Licensing Agreement with Ability Pharma 12
Ability Pharmaceuticals SL – Key Competitors 13
Ability Pharmaceuticals SL – Key Employees 14
Ability Pharmaceuticals SL – Locations And Subsidiaries 15
Head Office 15
Recent Developments 16
Product News 16
10/05/2017: Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France 16
Product Approvals 17
Sep 18, 2017: Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Key Facts 2
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ability Pharmaceuticals SL, Deals By Therapy Area, 2012 to YTD 2018 8
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Ability Pharma to Raise USD10.98 Million in Series A Financing 10
Ability Pharma Raises US$1.3 Million In Second Round Of Financing 11
SciClone Pharma Enters into Licensing Agreement with Ability Pharma 12
Ability Pharmaceuticals SL, Key Competitors 13
Ability Pharmaceuticals SL, Key Employees 14

List of Figures
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Ability Pharmaceuticals SL:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The Advisory Board Company:企業の戦略的SWOT分析
    The Advisory Board Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Global Petroleum Ltd (GBP):企業の財務・戦略的SWOT分析
    Summary Global Petroleum Ltd (Global Petroleum) is an oil and gas company that offers oil and gas exploration and development services. It operates through a portfolio of oil and gas projects in offshore Namibia and others. Its Namibian Project is into petroleum and gas exploration and Juan de Nova …
  • DormaKaba Holding AG:企業の戦略・SWOT・財務情報
    DormaKaba Holding AG - Strategy, SWOT and Corporate Finance Report Summary DormaKaba Holding AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Georg Fischer AG:企業の戦略・SWOT・財務情報
    Georg Fischer AG - Strategy, SWOT and Corporate Finance Report Summary Georg Fischer AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • InnoPharma Inc-製薬・医療分野:企業M&A・提携分析
    Summary InnoPharma Inc (InnoPharma), a subsidiary of Pfizer Inc is a healthcare products provider that develops generic and pharmaceutical products. The company develops formulations, which include solutions, suspensions, lyophilized, emulsions, liposomes, lipid complexes, polypeptides and carbohydr …
  • Skanray Technologies Pvt Ltd-医療機器分野:企業M&A・提携分析
    Summary Skanray Technologies Pvt Ltd (Skanray) is a medical equipment manufacturing company that provides high frequency x-ray imaging systems, critical care devices, and primary healthcare and telemedicine compatible devices. The company’s product categories include defibrillator, ventilators, surg …
  • Haynes International Inc:企業の戦略・SWOT・財務分析
    Haynes International Inc - Strategy, SWOT and Corporate Finance Report Summary Haynes International Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • ACWA Power International:電力:M&Aディール及び事業提携情報
    Summary ACWA Power International (ACWA Power), a subsidiary of ACWA Holding is a power generation company that develops and operates power generation and desalinated water production plants. The company holds a generation portfolio of power and desalinated water. Its projects comprise in selecting i …
  • Hindustan Organic Chemicals Limited (HOCL):企業の財務・戦略的SWOT分析
    Hindustan Organic Chemicals Limited (HOCL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Meiji Seika Pharma Co Ltd:企業のM&A・事業提携・投資動向
    Meiji Seika Pharma Co Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Meiji Seika Pharma Co Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • Severn Trent Plc (SVT):企業の財務・戦略的SWOT分析
    Severn Trent Plc (SVT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Serodus ASA:製薬・医療:M&Aディール及び事業提携情報
    Summary Serodus ASA (Serodus) is a drug development company that develops treatments for unmet clinical needs in the areas of diabetes and diabetic comorbidities. The company’s pipeline products include SER150DN, an anti-inflammatory compound under development for diabetic nephropathy; SER130AMI, an …
  • CiMaas BV:製薬・医療:M&Aディール及び事業提携情報
    Summary CiMaas BV (CiMaas) develops cellular immunotherapies (vaccines) for the treatment of cancer. Its pipeline cellular therapeutic products include CIM101, a dendritic cell vaccine being developed using its proprietary maturation technology for the treatment of lung cancer; and CIM201, a haploid …
  • O’Reilly Automotive, Inc. (ORLY):企業の財務・戦略的SWOT分析
    Summary O'Reilly Automotive Inc (O’Reilly) is a provider of automotive parts. The company offers automotive parts, tools, equipment, supplies and accessories. The company offers various services such as battery diagnostic testing; battery, wiper and bulb replacement; check and engine light code extr …
  • Aero Simulation, Inc.:企業の戦略・SWOT・財務情報
    Aero Simulation, Inc. - Strategy, SWOT and Corporate Finance Report Summary Aero Simulation, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Caretech Holdings Plc (CTH):企業の財務・戦略的SWOT分析
    Summary Caretech Holdings Plc (CareTech) is a children and adult care service provider. The company offers solution for adults and solution for children and young people. its adult care services includes learning disability, mental health, acquired brain injury, eating disorders, sensory impairments …
  • Verona Pharma Plc (VRP):医療機器:M&Aディール及び事業提携情報
    Summary Verona Pharma Plc (Verona Pharma) is a clinical-stage biotechnology company, which focuses on the research, discovery and development of first-in-class therapeutic drugs for the treatment of chronic respiratory and inflammatory diseases. The company's lead candidate, RPL554 is a bronchodilat …
  • University of Aberdeen-製薬・医療分野:企業M&A・提携分析
    Summary University of Aberdeen (UOA) is an educational and research institution that offers undergraduate, graduate, postgraduate and research programs in a range of subjects. The university offers undergraduate and postgraduate courses in the areas of arts, creative arts, commerce, education, engin …
  • Edinburgh Molecular Imaging Ltd:製品パイプライン分析
    Summary Edinburgh Molecular Imaging Ltd (EM Imaging) is a clinical phase biotechnology company that develops optical molecular imaging technology. It is involved in the discovery and development of small molecules and peptides. The company designs agents to improve the diagnosis and treatment of can …
  • Snyder’s-Lance, Inc.:戦略・SWOT・企業財務分析
    Snyder's-Lance, Inc. - Strategy, SWOT and Corporate Finance Report Summary Snyder's-Lance, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆